|
Laurus Labs Limited (Lauruslabs.NS) DCF -Bewertung
IN | Healthcare | Drug Manufacturers - Specialty & Generic | NSE
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Laurus Labs Limited (LAURUSLABS.NS) Bundle
Bewerten Sie die finanziellen Aussichten von Laurus Labs Limited wie ein Experte! Dieser DCF-Taschenrechner (Lauruslabsns) verfügt über vorgefüllte Finanzdaten und bietet vollständige Flexibilität, um das Umsatzwachstum, WACC, Margen und andere wichtige Annahmen zu ändern, um sich an Ihren Projektionen anzupassen.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27,586.1 | 47,232.2 | 48,885.4 | 60,405.5 | 50,018.0 | 60,157.5 | 72,352.4 | 87,019.5 | 104,659.8 | 125,876.1 |
| Revenue Growth, % | 0 | 71.22 | 3.5 | 23.57 | -17.2 | 20.27 | 20.27 | 20.27 | 20.27 | 20.27 |
| EBITDA | 5,594.8 | 15,725.6 | 14,273.0 | 15,756.1 | 7,927.0 | 15,003.8 | 18,045.3 | 21,703.4 | 26,103.1 | 31,394.6 |
| EBITDA, % | 20.28 | 33.29 | 29.2 | 26.08 | 15.85 | 24.94 | 24.94 | 24.94 | 24.94 | 24.94 |
| Depreciation | 1,872.7 | 2,050.7 | 2,514.9 | 3,240.8 | 3,845.8 | 3,528.7 | 4,244.0 | 5,104.3 | 6,139.1 | 7,383.6 |
| Depreciation, % | 6.79 | 4.34 | 5.14 | 5.37 | 7.69 | 5.87 | 5.87 | 5.87 | 5.87 | 5.87 |
| EBIT | 3,722.1 | 13,674.9 | 11,758.1 | 12,515.3 | 4,081.2 | 11,475.1 | 13,801.3 | 16,599.1 | 19,964.0 | 24,011.0 |
| EBIT, % | 13.49 | 28.95 | 24.05 | 20.72 | 8.16 | 19.08 | 19.08 | 19.08 | 19.08 | 19.08 |
| Total Cash | 16.9 | 484.6 | 759.4 | 647.7 | 1,416.5 | 787.4 | 947.1 | 1,139.1 | 1,370.0 | 1,647.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 8,516.9 | 13,640.6 | 13,939.0 | 16,346.4 | 16,952.0 | 17,953.4 | 21,592.9 | 25,970.1 | 31,234.7 | 37,566.5 |
| Account Receivables, % | 30.87 | 28.88 | 28.51 | 27.06 | 33.89 | 29.84 | 29.84 | 29.84 | 29.84 | 29.84 |
| Inventories | 9,052.2 | 15,754.5 | 17,603.0 | 16,848.1 | 18,454.1 | 20,088.4 | 24,160.6 | 29,058.4 | 34,949.0 | 42,033.8 |
| Inventories, % | 32.81 | 33.36 | 36.01 | 27.89 | 36.89 | 33.39 | 33.39 | 33.39 | 33.39 | 33.39 |
| Accounts Payable | 6,156.3 | 11,786.9 | 8,763.7 | 7,106.5 | 10,512.4 | 11,788.6 | 14,178.3 | 17,052.5 | 20,509.3 | 24,666.9 |
| Accounts Payable, % | 22.32 | 24.96 | 17.93 | 11.76 | 21.02 | 19.6 | 19.6 | 19.6 | 19.6 | 19.6 |
| Capital Expenditure | -2,221.9 | -6,887.7 | -8,768.4 | -9,901.6 | -6,783.1 | -8,485.4 | -10,205.6 | -12,274.4 | -14,762.6 | -17,755.3 |
| Capital Expenditure, % | -8.05 | -14.58 | -17.94 | -16.39 | -13.56 | -14.11 | -14.11 | -14.11 | -14.11 | -14.11 |
| Tax Rate, % | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 | 32.07 |
| EBITAT | 3,236.0 | 10,337.6 | 8,977.3 | 8,917.0 | 2,772.2 | 8,676.6 | 10,435.5 | 12,551.0 | 15,095.3 | 18,155.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -8,525.9 | -694.9 | -2,446.3 | -1,053.5 | 1,029.2 | 2,360.3 | -848.0 | -1,019.9 | -1,226.7 | -1,475.3 |
| WACC, % | 9.58 | 9.51 | 9.52 | 9.49 | 9.47 | 9.51 | 9.51 | 9.51 | 9.51 | 9.51 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,117.6 | |||||||||
| Long Term Growth Rate, % | 3.50 | |||||||||
| Free cash flow (T + 1) | -1,527 | |||||||||
| Terminal Value | -25,387 | |||||||||
| Present Terminal Value | -16,116 | |||||||||
| Enterprise Value | -17,233 | |||||||||
| Net Debt | 24,385 | |||||||||
| Equity Value | -41,618 | |||||||||
| Diluted Shares Outstanding, MM | 540 | |||||||||
| Equity Value Per Share | -77.12 |
Benefits You Will Receive
- Customizable Excel Template: A dynamic Excel-based DCF Calculator featuring pre-loaded financials for Laurus Labs Limited (LAURUSLABSNS).
- Accurate Data: Access to historical performance data and future projections (highlighted in the yellow cells).
- Flexible Forecasting: Modify key assumptions such as revenue growth, EBITDA margin, and WACC.
- Instant Calculations: Quickly observe how your adjustments affect the valuation of Laurus Labs Limited (LAURUSLABSNS).
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts.
- User-Friendly Interface: Organized for easy navigation and straightforward use, complete with detailed instructions.
Key Features
- Authentic Laurus Labs Financial Data: Gain access to precise pre-loaded historical figures and future forecasts.
- Adjustable Forecast Variables: Modify the yellow-highlighted fields such as WACC, growth rates, and margin assumptions.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow analyses.
- Interactive Dashboard: Intuitive charts and summaries to effectively present your valuation findings.
- Designed for All Users: A user-friendly layout tailored for investors, CFOs, and consultants alike.
How It Operates
- 1. Access the Template: Download and open the Excel file featuring Laurus Labs Limited’s preloaded data.
- 2. Modify Assumptions: Update key parameters such as growth projections, WACC, and capital expenditures.
- 3. View Results in Real-Time: The DCF model automatically calculates intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to analyze different valuation results.
- 5. Present with Assurance: Share professional valuation insights to back your strategic decisions.
Why Choose This Calculator for Laurus Labs Limited (LAURUSLABSNS)?
- Reliable Data: Up-to-date Laurus Labs financials provide trustworthy valuation insights.
- Flexible Options: Customize crucial variables such as growth projections, WACC, and tax rates to fit your analysis.
- Efficient: Pre-configured calculations save you time and streamline your evaluation process.
- Professional Tool: Tailored for use by investors, financial analysts, and consultants.
- Easy to Use: Clear design and comprehensive instructions ensure accessibility for every user.
Who Can Benefit from Laurus Labs Limited (LAURUSLABSNS)?
- Investors: Make informed investment choices with our industry-leading valuation tools.
- Financial Analysts: Streamline your analysis process with our customizable pre-built DCF model.
- Consultants: Effortlessly modify templates for impactful client presentations or reports.
- Pharmaceutical Enthusiasts: Enhance your knowledge of valuation methodologies through practical, real-world applications.
- Educators and Students: Utilize our resources as an effective learning aid in pharmaceutical finance courses.
Contents of the Template
- Pre-Filled DCF Model: Laurus Labs Limited’s financial data preloaded for immediate analysis.
- WACC Calculator: Comprehensive calculations for the Weighted Average Cost of Capital.
- Financial Ratios: Assess Laurus Labs Limited’s profitability, leverage, and operational efficiency.
- Editable Inputs: Modify assumptions like growth rates, profit margins, and capital expenditures to tailor scenarios.
- Financial Statements: Access annual and quarterly reports to facilitate in-depth analysis.
- Interactive Dashboard: Effortlessly visualize crucial valuation metrics and outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.